New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
Jessica Frau,* Giancarlo Coghe,* Lorena Lorefice, Giuseppe Fenu, Eleonora Cocco Multiple Sclerosis Center Binaghi Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy *These authors contributed equally to this work Abstract: Multiple Sclerosis (MS) i...
Guardado en:
Autores principales: | Frau J, Coghe G, Lorefice L, Fenu G, Cocco E |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf69616510ef491d8828c9114da9bd3e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
por: Duarte Diana Borges, et al.
Publicado: (2021) -
CLINICAL AND IMMUNOLOGICAL ASPECTS OF T C ELL-BASED VACCINE THERAPY IN PATIENTS WITH PROGREDIENT MULTIPLE SCLEROSIS
por: G. Seledtsova, et al.
Publicado: (2014) -
Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
por: Mosche Pompsch, et al.
Publicado: (2021) -
Multiple sclerosis international
Publicado: (2010) -
Real living with multiple sclerosis
Publicado: (1993)